EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Global Hemp Group (GBHPF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Global Hemp Group $0.00, price $0.00, upside +20.0%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

GH Global Hemp Group logo Thin data Oct 2, 2026

Global Hemp Group

GBHPF · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value $0.0001 · Undervalued (+20.0%)
!Quality 31/100
!Mixed Growth (revenue 5y +19.5 %/yr)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (1/4)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Global Hemp Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1.54 $0.0001 Fair Value $0.0001 Jun 2020 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range $0.0001 – $1.54 · fair‑value band $0.0001 – $0.0001 · the $0.0001 price screens below the $0.0001 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.

Follow Global Hemp in your weekly email

Every Wednesday you see whether Global Hemp is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Global Hemp Group Inc. engages in health and wellness, and industrial hemp businesses. The Industrial Hemp division primarily focuses on the environmental uses of hemp for construction and bio-energy sources for carbon-negative footprint.

Show more

Global Hemp Group Inc. engages in health and wellness, and industrial hemp businesses. The Industrial Hemp division primarily focuses on the environmental uses of hemp for construction and bio-energy sources for carbon-negative footprint. The Health and Wellness Division focuses on the acquisition of exclusive licensing of patents and IP for the commercialization of hemp formulations that have been independently pre-clinically tested. The company was formerly known as Arris Holdings Inc. and changed its name to Global Hemp Group Inc. in March 2014. Global Hemp Group Inc. was incorporated in 2009 and is headquartered in North Vancouver, Canada.

Stock analysis

Global Hemp Group (GBHPF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 16.7% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 88/100, which puts the evidence level at low.

Scenario range: $0.0001 (bear) to $0.0001 (bull), the price of $0.0001 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Global Hemp Group reported revenue of C$0 in FY2023 versus C$2.6K in FY2019. Reported net income was −C$2.6M in FY2023.

Key figures

Market cap $2.4K · EPS (TTM) $−0.1200 · Return on equity −1,205% · Return on assets (EBIT) −272% · Revenue (TTM) $1 · Free cash flow −$469K · Net debt $693K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 100% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 20%, GBHPF screens cheaper than that median.

Notify me when GBHPF reaches fair value

Put GBHPF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 31/100

Of which business quality 28 · Market factors (momentum, volatility) 8

Profitability 0
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 12
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 25
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 21/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,015.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.5%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
not computed

Watch GBHPF, get fair value alerts →

Compare Global Hemp Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside +20.0% · Above median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −95.2% · Bottom 25%
Operating margin (TTM) 0.0% · Below median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)60 · sector 14
FUTURE (revenue growth)0 · sector 24
PAST (return on equity)0 · sector 28
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.19 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Global Hemp Group · Fair Value
$0.0001 +17%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Global Hemp Group Fair Value". https://www.fairvalue-calculator.com/stock/GBHPF

Frequently asked questions

Is Global Hemp Group (GBHPF) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of $0.0001 versus the last price from Sep 25, 2026 of $0.0001, about +20% upside (undervalued).
What is the fair value of GBHPF?
Our model-based fair value for Global Hemp Group is $0.0001 (as of Oct 2, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0001.
What is the quality score of GBHPF?
Global Hemp Group has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Global Hemp Group (GBHPF)?
Our model-based price target is the fair value of $0.0001 (as of Oct 2, 2026) from 2 valuation models. Cautious scenario $0.0001, optimistic scenario $0.0001. It is a calculation from audited fundamentals, not an analyst target.
What is the Global Hemp Group stock forecast for 2026?
Our models put fair value at $0.0001, about +20% upside versus the last price from Sep 25, 2026 of $0.0001 (undervalued). Cautious scenario $0.0001, optimistic scenario $0.0001. The calculation is refreshed regularly with new filings.
What is the revenue of Global Hemp Group (GBHPF)?
Global Hemp Group reported trailing-twelve-month revenue of about $1 (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Global Hemp Group (GBHPF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Global Hemp Group it is $0.0001 per share (as of Oct 2, 2026), against a price of $0.0001. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Global Hemp Group stock overvalued or undervalued in 2026?
As of Oct 2, 2026, GBHPF trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +20% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GBHPF?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Global Hemp Group the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Global Hemp Group worth?
The market values Global Hemp Group at about $2.4K (market capitalisation, as of Oct 2, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
What do the bullish and bearish scenarios say about GBHPF?
Our models span a range for Global Hemp Group: cautious scenario $0.0001, base $0.0001, optimistic $0.0001 per share (as of Oct 2, 2026, price $0.0001). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Global Hemp Group (GBHPF)?
Balance-sheet figures for Global Hemp Group (as of Oct 2, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is GBHPF from its 52-week high?
Global Hemp Group trades at $0.0001, about 100% below its 52-week high of $0.0400 and at the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to Global Hemp Group?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Global Hemp Group stock attractive at the current price?
The data as of Oct 2, 2026: price $0.0001, calculated fair value $0.0001 (+20%), Quality Score 31/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GBHPF calculated?
We run Global Hemp Group through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Global Hemp Group currently trades 17 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Global Hemp Group (GBHPF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0001. Our model-based fair value is $0.0001, about +20% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Global Hemp Group right now?
The price is below even our cautious bear case ($0.0001). The market is more pessimistic than our downside scenario. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Global Hemp Group

How large is the market capitalisation of Global Hemp Group (GBHPF)?
The market capitalisation of Global Hemp Group is $2.4K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Global Hemp Group (GBHPF)?
Earnings per share at Global Hemp Group are $−0.1200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Global Hemp Group (GBHPF)?
The return on equity (ROE) of Global Hemp Group is −1,205% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Global Hemp Group (GBHPF)?
On an EBIT basis the return on assets of Global Hemp Group is −272% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Global Hemp Group (GBHPF) generate?
The free cash flow of Global Hemp Group is −$469K (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Global Hemp Group (GBHPF) carry?
The net debt of Global Hemp Group is $693K (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Global Hemp Group in the live analysis

One click puts Global Hemp Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.